布地奈德雾化吸入剂联合阿奇霉素对支原体肺炎患者的临床疗效
Clinical efficacy of budesonide nebulizer combined with Azithromycin in patients with mycoplasma pneumonia
王恩光 1张俣 1王丽萍 1王海旭1
作者信息
- 1. 841100 新疆维吾尔自治区乌鲁木齐市,新疆医科大学第五附属医院呼吸与危重症医学科
- 折叠
摘要
目的 探讨布地奈德雾化吸入剂+阿奇霉素对支原体肺炎患者的临床疗效及对肺功能及血清炎症因子水平的影响.方法 选择2022年2月-2023年2月医院收治的支原体肺炎患者120例为研究对象.在性别、年龄、病程、白细胞计数和体温等基线资料组间均衡可比的原则下,以随机数字表法分为观察组和对照组.对照组 56 例患者接受阿奇霉素治疗,观察组64例患者接受布地奈德雾化吸入剂+阿奇霉素治疗.比较两组患者治疗前后肺功能指标水平、血清炎症因子水平、症状消退速度和不良反应发生率.结果 两组患者性别、年龄、病程、白细胞计数和体温比较,差异均无统计学意义(P>0.05).治疗前,两组患者肺功能指标及血清炎症因子水平比较,差异均无统计学意义(P>0.05);治疗后,观察组患者FEV1、FEV1%水平均高于对照组,且TNF-α、IL-6水平均低于对照组,差异均有统计学意义(P<0.05).观察组患者止咳、退热、止痰、头晕头痛消退时间均短于对照组,差异均有统计学意义(P<0.05).两组患者不良反应发生率比较,差异无统计学意义(P>0.05).结论 布地奈德雾化吸入剂联合阿奇霉素有助于改善支原体肺炎患者肺功能及血清炎症因子水平,缩短其临床症状消退时间,且不会增加药物不良反应发生率.
Abstract
Objective To explore the clinical efficacy of budesonide nebulized inhaler+azithromycin on patients with mycoplasma pneumonia and the effects on lung function and serum inflammatory factor levels.Methods 120 patients with mycoplasma pneumonia admitted to our hospital from February 2022 to February 2023 were selected as study subjects.Under the principle of balanced comparability between groups for baseline data such as gender,age,disease duration,white blood cell count and body temperature,they were divided into observation and control groups by random number table method.Fifty-six patients in the control group received azithromycin treatment,and 64 patients in the observation group received budesonide nebulized inhaler+azithromycin treatment.Compare the level of lung function indexes,serum inflammatory factor level,the speed of symptom subsidence and the incidence of adverse reactions before and after treatment in the two groups.Results Comparison of gender,age,disease duration,white blood cell count and body temperature of the two groups of patients showed no statistically significant differences(P>0.05).Before treatment,there was no statistically significant difference between the lung function indexes and serum inflammatory factor levels of the two groups(P>0.05);after treatment,the FEV1 and FEV1%levels of the patients in the observation group were higher than those of the control group,and the levels of TNF-α and IL-6 were lower than those of the control group,and the differences were statistically significant(P<0.05).The time to stop cough,reduce fever,stop sputum,dizziness and headache subsided in patients of the observation group was shorter than that of the control group,and the differences were all statistically significant(P<0.05).Comparison of the incidence of adverse reactions between the two groups of patients,the difference is not statistically significant(P>0.05).Conclusion Budesonide nebulized inhaler combined with azithromycin helps to improve the lung function and serum inflammatory factor level of patients with mycoplasma pneumonia,shorten the time for their clinical symptoms to subside,and does not increase the incidence of adverse drug reactions.
关键词
布地奈德雾化吸入剂/阿奇霉素/支原体肺炎/肺功能/炎症因子水平Key words
Budesonide nebulized inhaler/Azithromycin/Mycoplasma pneumonia/Lung function/Inflammatory factor level引用本文复制引用
出版年
2024
NETL
NSTL
万方数据